Abnormal loss of weight adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From November 2007 to June 2026, FDA received 6,676 adverse event reports that record the MedDRA preferred term Abnormal loss of weight. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 526 reports in the 12 months to June 2026 and 313 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 958 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 526 (under 0.1%) record this term. Reports for patients 75 and over were 14.6% of the reports that record this term and 9.5% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 89 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Abnormal loss of weight name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetylsalicylic Acid		35
Adempas	Soluble guanylate cyclase stimulator	42
Allopurinol	Xanthine oxidase inhibitor	36
Amlodipine	Calcium channel blocker	58
Arava	Antirheumatic agent	83
Aspirin	Nonsteroidal anti-inflammatory drug	110
Atorvastatin		138
Avonex	Interferon beta	25
Bisoprolol	beta-Adrenergic blocker	33
Budesonide	Corticosteroid	35
Ciprofloxacin	Fluoroquinolone antibacterial	67
Clopidogrel	P2Y12 platelet inhibitor	63
Combivent		70
Dianeal Low Calcium Peritoneal Dialysis Solution with Dextrose		25
Diclofenac	Nonsteroidal anti-inflammatory drug	79
Diclofenac potassium	Nonsteroidal anti-inflammatory drug	55
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	43
Duragesic		55
Duragesic-100		49
Enbrel	Tumor necrosis factor blocker	115
Esomeprazole	Proton pump inhibitor	27
Fentanyl	Opioid agonist	31
Fentanyl-100		32
Finasteride	5-alpha reductase inhibitor	28
Fluoxetine	Serotonin reuptake inhibitor	56
Fosamax	Bisphosphonate	36
Furosemide	Loop diuretic	79
Gabapentin	Anti-epileptic agent	73
Gold	Standardized chemical allergen	75
Gold Sodium Thiomalate		46
Humira		217
Hydroxychloroquine	Antimalarial	49
Hydroxychloroquine sulfate	Antimalarial	55
Ibuprofen	Nonsteroidal anti-inflammatory drug	85
Infliximab	Tumor necrosis factor blocker	29
Invokana	Sodium-Glucose cotransporter 2 inhibitor	182
Jakafi	Janus kinase inhibitor	44
Januvia	Dipeptidyl peptidase 4 inhibitor	31
Jardiance	Sodium-Glucose cotransporter 2 inhibitor	185
Lansoprazole	Proton pump inhibitor	73
Lialda	Aminosalicylate	25
Metformin	Biguanide	76
Methotrexate	Folate analog metabolic inhibitor	185
Methotrexate sodium	Folate analog metabolic inhibitor	29
Metronidazole	Nitroimidazole antimicrobial	25
Motrin	Nonsteroidal anti-inflammatory drug	52
Mounjaro	GLP-1 receptor agonist	41
Mycophenolate mofetil	Antimetabolite immunosuppressant	45
Naprosyn		55
Naproxen	Nonsteroidal anti-inflammatory drug	62
Nexavar	Kinase inhibitor	31
Ofev	Kinase inhibitor	214
Omeprazole	Proton pump inhibitor	104
Opsumit	Endothelin receptor antagonist	33
Ozempic	GLP-1 receptor agonist	174
Plaquenil	Antimalarial	50
Pradaxa	Direct thrombin inhibitor	67
Prednisolone	Corticosteroid	54
Prednisone	Corticosteroid	57
Ramipril	Angiotensin converting enzyme inhibitor	66
Remicade	Tumor necrosis factor blocker	184
Revlimid	Thalidomide analog	58
Risperidone	Atypical antipsychotic	29
Sertraline	Serotonin reuptake inhibitor	84
Simponi	Tumor necrosis factor blocker	27
Simvastatin	HMG-CoA reductase inhibitor	104
Sodium Aurothiomalate		39
Spironolactone	Aldosterone antagonist	25
Stelara	Interleukin-12 antagonist	29
Stivarga	Kinase inhibitor	26
Sulfamethoxazole		39
Sulfamethoxazole and trimethoprim	Dihydrofolate reductase inhibitor antibacterial	25
Sulfamethoxazole, trimethoprim	Dihydrofolate reductase inhibitor antibacterial	32
Tacrolimus	Calcineurin inhibitor immunosuppressant	34
Tecfidera		34
Tiotropium bromide	Anticholinergic	222
Topamax		57
Topiramate		47
Tradjenta	Dipeptidyl peptidase 4 inhibitor	28
Tramadol		57
Tramadol hydrochloride	Opioid agonist	39
Trimipramine	Tricyclic antidepressant	31
Ultram		28
Vedolizumab	Integrin receptor antagonist	30
Vitamin c	Vitamin C	47
Vyvanse	Central nervous system stimulant	57
Warfarin	Vitamin K antagonist	28
Wegovy	GLP-1 receptor agonist	91
Xarelto	Factor Xa inhibitor	202

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 59 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Abnormal loss of weight name, in order of name
Class	Reports with this term
5-alpha reductase inhibitor	46
Aldosterone antagonist	31
Allylamine antifungal	25
Aminosalicylate	45
Angiotensin 2 receptor blocker	79
Angiotensin converting enzyme inhibitor	85
Anti-epileptic agent	97
Anticholinergic	236
Antimalarial	154
Antimetabolite immunosuppressant	61
Antirheumatic agent	95
Atypical antipsychotic	161
Benzodiazepine	35
beta-Adrenergic blocker	51
Biguanide	113
Bisphosphonate	49
Calcineurin inhibitor immunosuppressant	38
Calcium channel blocker	62
CD20-directed cytolytic antibody	45
Central nervous system stimulant	87
Corticosteroid	190
Cytochrome P450 17A1 inhibitor	25
Dihydrofolate reductase inhibitor antibacterial	92
Dipeptidyl peptidase 4 inhibitor	93
Direct thrombin inhibitor	67
Endothelin receptor antagonist	74
Factor Xa inhibitor	246
Fluoroquinolone antibacterial	76
Folate analog metabolic inhibitor	224
GLP-1 receptor agonist	405
HMG-CoA reductase inhibitor	145
Integrin receptor antagonist	51
Interferon beta	37
Interleukin-12 antagonist	29
Janus kinase inhibitor	57
Kinase inhibitor	328
Loop diuretic	83
Nitroimidazole antimicrobial	25
Nonsteroidal anti-inflammatory drug	501
Opioid agonist	164
Osmotic laxative	32
P2Y12 platelet inhibitor	74
Peroxisome proliferator receptor alpha agonist	25
Platinum-based drug	28
Programmed death Receptor-1 blocking antibody	49
Prostacycline vasodilator	58
Proton pump inhibitor	226
RANK ligand inhibitor	27
Serotonin and norepinephrine reuptake inhibitor	47
Serotonin reuptake inhibitor	210
Sodium-Glucose cotransporter 2 inhibitor	390
Soluble guanylate cyclase stimulator	42
Standardized chemical allergen	75
Thalidomide analog	70
Tricyclic antidepressant	31
Tumor necrosis factor blocker	375
Vitamin C	69
Vitamin K antagonist	44
Xanthine oxidase inhibitor	36

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Abnormal loss of weight, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Abnormal loss of weight
Age	Reports	Share
Under 2	23	0.3%
2 to 11	39	0.6%
12 to 17	78	1.2%
18 to 44	727	10.9%
45 to 64	1,438	21.5%
65 to 74	1,055	15.8%
75 and over	978	14.6%
Age not given	2,338	35%

Sex of the patient in the reports that record Abnormal loss of weight
Sex	Reports	Share
Female	3,619	54.2%
Male	2,551	38.2%
Unknown or not given	506	7.6%

Age and sex are as the report gives them. 60.1% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Abnormal loss of weight: adverse event reports that record this term. https://reportedreactions.com/reaction/abnormal-loss-of-weight/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Abnormal loss of weight mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page